Jin Feng, Zhu Hui, Shi Fang, Kong Li, Yu Jinming
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, University of Jinan, Jinan, Shandong Province, People's Republic of China; Shandong Academy of Medical Sciences, University of Jinan, Jinan, Shandong Province, People's Republic of China.
Clin Interv Aging. 2016 Feb 19;11:167-73. doi: 10.2147/CIA.S97363. eCollection 2016.
The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous non-small-cell lung cancer (NSCLC).
We retrospectively reviewed the treatment of 42 elderly patients with relapsed squamous NSCLC, who received nab-paclitaxel monotherapy as a second-line treatment from January 2010 to March 2014. A dose of 100 mg/m(2) nab-paclitaxel was administered weekly on days 1, 8, and 15, followed by 1 week of rest. The protocol was maintained for at least two cycles.
The overall response rate (ORR) and the disease control rate (DCR) were 21.43% (9/42) and 47.62% (20/42), respectively. The median progression-free survival (PFS) and overall survival (OS) were 6.6 and 10.9 months, respectively. In the subgroup analysis, there was no significant difference in ORR, DCR, PFS, and OS, accounting for the first-line therapy factors (taxane agent, radiotherapy, or surgery). There was a statistically significant difference in DCR for stages III and IV (62.96% vs 20%, P=0.008), but there was no such difference in either PFS or OS. The ORR of 29 patients receiving more than three cycles of treatment was higher than that of those receiving less than three cycles of treatment (31.03% vs 0%, P=0.038), and there was a significant difference in PFS (7.6 vs 4.9 months, P=0.004) and OS (11.7 vs 8.9 months, P=0.002). No hypersensitivity reactions or treatment-related grade 4 adverse events were reported.
Nab-paclitaxel monotherapy administered weekly at a dose of 100 mg/m(2) is shown to be an effective and safe regimen for elderly patients with relapsed squamous NSCLC, especially for patients with stage III disease or good performance status.
本回顾性研究旨在调查每周给药的白蛋白结合型紫杉醇作为老年复发鳞状非小细胞肺癌（NSCLC）患者二线化疗的抗癌效果和毒性。
我们回顾性分析了2010年1月至2014年3月期间接受白蛋白结合型紫杉醇单药二线治疗的42例老年复发鳞状NSCLC患者的治疗情况。白蛋白结合型紫杉醇剂量为100mg/m²，于第1、8和15天每周给药一次，随后休息1周。该方案至少维持两个周期。
总缓解率（ORR）和疾病控制率（DCR）分别为21.43%（9/42）和47.62%（20/42）。中位无进展生存期（PFS）和总生存期（OS）分别为6.6个月和10.9个月。在亚组分析中，ORR、DCR、PFS和OS在考虑一线治疗因素（紫杉烷类药物、放疗或手术）方面无显著差异。III期和IV期的DCR有统计学显著差异（62.96%对20%，P = 0.008），但PFS或OS无此差异。接受三个以上周期治疗的29例患者的ORR高于接受少于三个周期治疗的患者（31.03%对0%，P = 0.038），PFS（7.6对4.9个月，P = 0.004）和OS（11.7对8.9个月，P = 0.002）有显著差异。未报告过敏反应或与治疗相关的4级不良事件。
每周一次剂量为100mg/m²的白蛋白结合型紫杉醇单药治疗对老年复发鳞状NSCLC患者，尤其是III期疾病或身体状况良好的患者，是一种有效且安全的方案。
